Trading Signals: VBIV Stock Price Prediction and Forecast (Thu. May. 4, 2006 - Fri. Jul. 24, 2020)(VBI Vaccines Inc)
| VBIV latest price $5.0050 (3.09%) ($4.5300 - $5.0500) on Thu. Jul. 16, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.89% (three month average) | RSI | 79 | Latest Price | $5.0050(3.09%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | VBIV advances 5.2% a day on average for past five trading days. | Weekly Trend | VBIV advances 21.6% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support VBIV advance at 0% a week (0% probability) ACES(-12%) UNG(-55%) SIL(30%) XBI(10%) VWO(67%) | Factors Impacting VBIV price | VBIV will decline at least -4.445% in a week (0% probabilities). IBB(-25%) IBUY(2%) ARKK(5%) GDXJ(17%) GDX(28%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -4.445% (StdDev 8.89%) | Hourly BBV | 0 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $4.42(13.24%) | 10 Day Moving Average | $4.05(23.58%) | 20 Day Moving Average | $3.47(44.24%) | To recent high | 0% | To recent low | 0% | Market Cap | $1.154b | | | | VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.VBI's COVID-19 vaccine candidate, VBI-2901, is noteworthy because it could potentially also confer immunity to other coronaviruses which cause diseases like MERS (Middle Eastern Respiratory Syndrome). More importantly, VBI appears to be facing a bottleneck either in its preclinical research or its vaccine manufacturing capabilities. VBI doesn't expect to have the necessary clinical study materials assembled for its COVID-19 vaccine trial before the fourth quarter, meaning that it's roughly a quarter behind Vaxart in the development process. |